Blood-Based Biomarker
Blood Based Biomarker for Alzheimer's disease were unreachable, but new findings indicate that they may become a reality. Convincing evidence obtained by novel high-sensitivity assays have emerged, not just with remarkable consistency across various cohorts, but also independently of the particular analytical technique utilized. Blood concentrations of amyloid and phosphorylated tau proteins correlate with CSF concentrations and amyloid-PET or tau-PET scans. Furthermore, blood-based neurodegenerative biomarkers such as neurofilament light chain and glial fibrillary acidic protein appear to give information on disease progression as well as the possibility for monitoring therapy effects.
Explore the Blog- https://bit.ly/3uZSQB4
